<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463942</url>
  </required_header>
  <id_info>
    <org_study_id>TBE-LB2014</org_study_id>
    <nct_id>NCT02463942</nct_id>
  </id_info>
  <brief_title>Tick-borne Encephalitis and Positive Borrelial Antibodies</brief_title>
  <acronym>TBE-LB2014</acronym>
  <official_title>Management of Patients With Tick-borne Encephalitis and Positive Anti-Lyme Borreliae Antibody Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana School of Medicine, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Slovenia, tick-borne encephalitis and Lyme borreliosis are both endemic diseases with high
      incidence rates and they are both transmitted by a bite of infected Ixodes ricinus tick. In
      clinical practice, tick-borne encephalitis is confirmed by demonstration of tick-borne
      encephalitis antibodies in serum of a patient with compatible clinical presentation and
      cerebrospinal pleocytosis. Patients with Lyme meningitis or meningoradiculitis also have
      cerebrospinal pleocytosis, however the presence of borrelial antibodies in serum does not
      attest Lyme neuroborreliosis.

      Patients with tick-borne encephalitis and positive borrelial antibodies in serum, but not
      fulfilling criteria for Lyme neuroborreliosis, are often being treated with antibiotics in
      several European countries due to the possibility of double infection. The investigators
      hypothesise that such patients do not benefit from antibiotics. Such an approach may appear
      safe regarding the possibility of borrelial infection, however it can also be associated with
      detrimental consequences such as antibiotic related adverse reactions, negative
      epidemiological impact on bacterial resistance, and intravenous catheter related
      complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective manifestations of Lyme borreliosis</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tick-borne Encephalitis</condition>
  <arm_group>
    <arm_group_label>Doxycycline, Doxy®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antibiotics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.</description>
    <arm_group_label>Doxycycline, Doxy®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symptomatic therapy</intervention_name>
    <description>Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.</description>
    <arm_group_label>No antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
    <arm_group_label>No antibiotics</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  clinical picture compatible with tick-borne encephalitis,

          -  clear cerebrospinal fluid,

          -  cerebrospinal pleocytosis (leucocytes in cerebrospinal fluid &gt;5 x 106/)L,

          -  positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against
             tick-borne encephalitis virus,

          -  positive serum IgG antibodies against Lyme borreliae.

        Exclusion Criteria:

          -  isolation of B.burgdorferi sensu lato from cerebrospinal fluid,

          -  positive intrathecal borrelial antibody production index,

          -  seroconversion of borrelial IgG antibodies,

          -  presence of erythema migrans and/or borrelial lymphocytoma in the last month,

          -  Bannwarth syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daša Stupica, MD, PhD</last_name>
    <phone>+386 1 5222110</phone>
    <email>dasa.stupica@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franc Strle, MD, PhD</last_name>
    <phone>+386 1 5222610</phone>
    <email>franc.strle@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana, Department of Infectious Diseases</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daša Stupica, MD, PhD</last_name>
      <phone>+386 1 522 2110</phone>
      <email>dasa.stupica@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Franc Strle, MD, PhD</last_name>
      <phone>+386 1 522 2610</phone>
      <email>franc.strle@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Daša Stupica, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Franc Strle</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

